FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/Peptide Therapy Shows Promise in Combating Opioid Use Disorder
返回研究图书馆

Peptide Therapy Shows Promise in Combating Opioid Use Disorder

May 25, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

Peptide Therapy Shows Promise in Combating Opioid Use Disorder

Recent developments in peptide research have sparked interest with a new clinical trial evaluating tirzepatide as an adjunct treatment for individuals struggling with opioid use disorder (OUD). The study, led by Dr. T. John Winhusen and sponsored through the National Institute on Drug Abuse (NIDA), aims to assess whether adding tirzepatide can improve outcomes when used alongside buprenorphine.

Background

Peptide therapy has been gaining traction in medical research due to its potential for targeted treatment approaches that minimize side effects. Tirzepatide, a GLP-1 receptor agonist and GIP receptor antagonist, is currently approved by the FDA for treating type 2 diabetes and obesity but shows promise beyond these applications. Research suggests it may have neuroprotective properties beneficial in managing addiction.

Opioid use disorder affects millions of people worldwide, with buprenorphine being a standard treatment option that helps mitigate withdrawal symptoms and reduces cravings. However, many patients find the need for additional support to fully recover from OUD. The introduction of tirzepatide as an adjunct therapy could provide a new avenue for enhancing patient outcomes.

Key Details

The research study, currently recruiting participants through ClinicalTrials.gov under identifier NCT06651177, focuses on evaluating the impact of tirzepatide compared to placebo in patients with OUD. This Phase 2 trial will investigate how adding tirzepatide influences retention rates in treatment programs, substance use patterns, and sleep quality.

Participants will be monitored over an extended period to assess if combining buprenorphine with tirzepatide can lead to better long-term outcomes compared to using buprenorphine alone. The study emphasizes the importance of addressing multiple facets of OUD recovery, including psychological support and pharmacological intervention.

Key Takeaways

  • Novel Adjunct Therapy: This trial explores the potential benefits of using tirzepatide alongside established treatments like buprenorphine.
  • Improved Outcomes: Researchers aim to determine if adding a peptide therapy can enhance patient retention in treatment programs and reduce substance use.
  • Sleep Quality Assessment: The study also focuses on evaluating sleep patterns, recognizing their critical role in overall recovery from OUD.
  • Scientific Community Interest: This research could attract significant attention within the scientific community due to its innovative approach combining established treatments with new peptide therapies.

What This Means

For the peptide therapy and research community, this trial represents a pivotal moment. If successful, it would highlight the versatility of peptides in addressing complex medical conditions beyond their current applications. Additionally, the findings could pave the way for regulatory bodies like the FDA to consider approving similar adjunctive treatments for OUD.

Moreover, the study underscores the growing importance of integrating multi-faceted approaches in treating addiction and mental health disorders. As peptide research continues to advance, such innovative clinical trials will likely become more common, offering hope to patients seeking effective treatment options.

---

Source: ClinicalTrials.gov — Published 2026-05-22

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。